This handout is for cardiogenic shock — takotsubo with dynamic lvot obstruction (sam-mediated). Your care team identified this based on: bedside echo: apical ballooning + basal hyperkinesis + lvot gradient ≥30 mmhg at rest (or ≥50 mmhg with provocation) + sam of mitral valve — takotsubo with dynamic lvot obstruction.
Other reasons your team may use this plan: tte/tee: systolic anterior motion of anterior mitral leaflet + posteriorly directed mr jet in patient with confirmed takotsubo apical ballooning; patient with takotsubo cs deteriorating paradoxically after inotrope/iabp initiation (drop in bp + rising lactate) — diagnostic clue to occult lvot obstruction; obtain stat echo with doppler; postmenopausal female (~90% takotsubo predominance) presenting with shock + new harsh systolic murmur (mistaken for as or papillary rupture) + apical akinesia → lvot-obstruction takotsubo.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| phenylephrine | 40–360 µg/min IV (titrate to MAP ≥65 and falling LVOT gradient) | IV | continuous | Pure α-agonist raises afterload without inotropy → reduces dynamic LVOT gradient; ESC HFA 2016 Lyon position is the definitive source; mechanistic parallel to HOCM acute management |
| esmolol | 500 µg/kg IV bolus → 50–200 µg/kg/min infusion | IV | continuous, titrate to HR 60–80 and gradient resolution | β1-blocker reduces septal hyperkinesis and slows HR → larger LV cavity + reduced gradient; esmolol short-acting allows rapid titration; this is the one Takotsubo subset where β-blocker is the right answer (vs general AVOID rule) |
| isotonic crystalloid (LR or NS) | 250–500 mL bolus, repeat until gradient drops or pulmonary edema | IV | reassess after each bolus with serial echo | Increased preload enlarges LV cavity → reduces dynamic gradient; CONTRAINDICATED in non-LVOT Takotsubo with pulmonary edema; clinical clue: BP improves with each bolus in LVOT-subtype |
| warfarin | 5 mg daily; INR target 2–3 | PO | daily × 3 mo | AHA 2022 Class IIa for LV thrombus (extrapolated to apical-ballooning Takotsubo); 3-mo course typically sufficient given recovery timeline |
| apixaban | 5 mg BID (or 2.5 mg BID per dose-reduction criteria) | PO | BID × 3 mo for mural thrombus prophylaxis | Off-label-but-rational DOAC alternative for LV thrombus prophylaxis in Takotsubo recovery |
| carvedilol | 3.125 mg BID after LVOT gradient resolves and patient off IV esmolol | PO | BID, titrate | Long-term β-blocker more reasonable in LVOT-subtype Takotsubo than general Takotsubo; theoretical recurrence-prevention rationale per Lyon 2016 ESC HFA position |
| metoprolol succinate | 25 mg daily, titrate to 100 mg daily | PO | daily | Alternative oral β-blocker for LVOT-subtype Takotsubo recovery maintenance per Lyon 2016 ESC HFA position |
Plan: Takotsubo CS with dynamic LVOT obstruction — INVERTED physiology bundle: PRELOAD-DEPENDENT + AFTERLOAD-RESPONSIVE; fluids + pure α-pressor + β-blocker; AVOID inotropes/IABP/diuretics/nitrates
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Repeat echo at 1–4 wks to confirm complete LVOT gradient resolution + LV recovery (faster than non-LVOT Takotsubo); psych follow-up; long-term β-blocker (carvedilol/metoprolol succinate) is more reasonable in this subset given LVOT-recurrence risk than in general Takotsubo (Lyon 2016 ESC HFA position favors continued β-blocker in LVOT-subtype recovery); recurrence ~5–10% over follow-up
Guideline: Lyon 2016 ESC HFA position statement on Takotsubo (definitive source for LVOT-subtype management); InterTAK consortium / Ghadri 2018 Eur Heart J expert consensus Part I + II; Templin NEJM 2015 PMID 26332547 (InterTAK registry); ACC/AHA 2022 HF Guideline; HOCM literature (Maron AHA 2020) for mechanistic LVOT obstruction parallel